XML 17 R7.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Operating activities:    
Net loss $ (92,427) $ (10,136)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:    
Depreciation 424 400
Amortization of right-of-use operating lease assets 448 501
Amortization of intangibles 2,924 2,908
Amortization of premium/discount on investment securities, net 747 (434)
Non-cash sublicensing expense   75,000
Stock-based compensation expense 23,402 32,923
Changes in operating assets and liabilities:    
Accounts receivable (3,553) (4,596)
Other current and long-term assets (2,026) (966)
Inventories (2,415) (4,014)
Accounts payable (6,001) (2,890)
Payable/receivable from Ionis Pharmaceuticals, Inc. 8,089 (26,812)
Income tax receivable (446)  
Accrued compensation (4,480) (1,062)
Accrued liabilities 576 2,128
Income taxes payable (888) (169)
Deferred revenue (1,902) (12,958)
Net cash (used in) provided by operating activities (77,528) 49,823
Investing activities:    
Purchases of short-term investments (215,329) (78,606)
Proceeds from maturity of short-term investments 118,637 100,043
Purchases of property, plant and equipment (558) (1,389)
Net cash (used in) provided by investing activities (97,250) 20,048
Financing activities:    
Proceeds from issuance of equity 3,649 7,409
Distribution to Ionis Pharmaceuticals, Inc.   (13,492)
Payments of tax withholdings related to exercise of employee stock awards (76)  
Net cash provided by (used in) financing activities 3,573 (6,083)
Effect of exchange rates on cash 83 (8)
Net (decrease) increase in cash and cash equivalents (171,122) 63,780
Cash, cash equivalents and restricted cash at beginning of period 309,250 88,838
Cash, cash equivalents and restricted cash at end of period 138,128 152,618
Supplemental disclosures of non-cash financing activities:    
Purchase of property, plant and equipment included in accounts payable 38  
Right-of-use assets obtained in exchange for lease liabilities   363
Cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets:    
Cash and cash equivalents 135,744 150,234
Restricted cash included in deposits and other assets 2,384 2,384
Cash, cash equivalents and restricted cash at end of period 138,128 $ 152,618
Ionis [Member]    
Supplemental disclosures of non-cash financing activities:    
Purchase of property, plant and equipment included in accounts payable $ 462